^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Hocena (antroquinonol)

Associations
Trials
Company:
Golden Biotechnology
Drug class:
EGFR inhibitor, MEK inhibitor, AKT inhibitor, AMPK activator, NF-κB inhibitor, RAS inhibitor, NRF2 activator
Related drugs:
Associations
Trials
2ms
Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer (clinicaltrials.gov)
P1/2, N=52, Active, not recruiting, Golden Biotechnology Corporation | Trial completion date: Mar 2024 --> Dec 2024
Trial completion date • Combination therapy • Metastases
|
albumin-bound paclitaxel • Hocena (antroquinonol)
5ms
In Vitro Assessment of 4-Acetyl-Antroquinonol B and Erinacine A in Suppressing Breast Cancer-Induced Osteoclastogenesis. (PubMed, Int J Med Mushrooms)
The results revealed that 4-AAQB and erinacine A effectively suppressed breast cancer-induced osteoclastogenesis and migration, and reduced TGF-β and MMP-9 production via Erk or JNK signaling transductions, specifically in breast cancer cells or in breast cancer cells-induced osteoclasts. Based on these findings, either 4-AAQB or erinacine A showed promise in preventing breast cancer metastases in bone.
Preclinical • Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • MMP9 (Matrix metallopeptidase 9)
|
Hocena (antroquinonol)
9ms
Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer (clinicaltrials.gov)
P1/2, N=52, Active, not recruiting, Golden Biotechnology Corporation | Trial completion date: Dec 2023 --> Mar 2024
Trial completion date • Combination therapy • Metastases
|
albumin-bound paclitaxel • Hocena (antroquinonol)
12ms
A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer. (ASCO-GI 2024)
In this phase I/II trial, antroquinonol plus Gem/Nab-P showed good efficacy in survival and less adverse events than a first-line strategy of Gem/Nab-P for mPC patients. Clinical trial information: NCT03310632. >Abbreviations: mPC, metastatic pancreatic cancer; Gem/Nab-P, gemcitabine and nab-paclitaxel.#, data from U.S. FDA-approved Supplemental New Drug Application (NDA 21660/S-037) dated March 21, 2013 for paclitaxel protein-bound particles for injectable suspension (albumin-bound), 100 mg/vial.
Clinical • P1/2 data • Combination therapy • Metastases
|
gemcitabine • albumin-bound paclitaxel • Hocena (antroquinonol)
1year
Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer (clinicaltrials.gov)
P1/2, N=52, Active, not recruiting, Golden Biotechnology Corporation | Trial primary completion date: Dec 2022 --> Dec 2023
Trial primary completion date • Combination therapy • Metastases
|
CA 19-9 (Cancer antigen 19-9)
|
albumin-bound paclitaxel • Hocena (antroquinonol)
over2years
Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer (clinicaltrials.gov)
P1/2, N=52, Active, not recruiting, Golden Biotechnology Corporation | Recruiting --> Active, not recruiting | Trial completion date: Jun 2022 --> Dec 2023 | Trial primary completion date: Jun 2022 --> Dec 2022
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
|
CA 19-9 (Cancer antigen 19-9)
|
albumin-bound paclitaxel • Hocena (antroquinonol)
over2years
Urokinase plasminogen activator induces epithelial-mesenchymal and metastasis of pancreatic cancer through plasmin/MMP14/TGF-β axis, which is inhibited by 4-acetyl-antroquinonol B treatment. (PubMed, Phytomedicine)
Accordingly, to extent of our knowledge and previous studies, we demonstrated that 4-AAQB is an anti Pan-Cancer drug, and may inhibit pancreatic cancer EMT and metastasis and serve as a new therapeutic approach for patients with late-stage pancreatic cancer.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • MMP14 (Matrix Metallopeptidase 14)
|
Hocena (antroquinonol)
over2years
4-Acetylantroquinonol B Suppresses Prostate Cancer Growth and Angiogenesis via a VEGF/PI3K/ERK/mTOR-Dependent Signaling Pathway in Subcutaneous Xenograft and In Vivo Angiogenesis Models. (PubMed, Int J Mol Sci)
Serum or vascular endothelial growth factor (VEGF)-induced VEGF receptor 2 (VEGFR2), phosphoinositide 3-kinase (PI3K)/Ak strain transforming (Akt), and extracellular signal-regulated kinase ½ (ERK ½) phosphorylation were attenuated by 4AAQB in both PC3 and HUVEC. In conclusion, 4AAQB is a potential candidate for prostate cancer therapy.
Preclinical • Journal
|
KDR (Kinase insert domain receptor)
|
Hocena (antroquinonol)
over2years
4-Acetylantroquinonol B enhances cell death and inhibits autophagy by downregulating the PI3K/Akt/MDR1 pathway in gemcitabine-resistant pancreatic cancer cells. (PubMed, Oncol Lett)
Vascular endothelial growth factor A (VEGFA) expression, cell migration, and invasion were also inhibited by the 4-AAQB incubation. Overall, this combination treatment strategy might represent a novel approach for GEM-resistant pancreatic cancer.
Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCC1 (ATP Binding Cassette Subfamily C Member 1) • HMGB1 (High Mobility Group Box 1)
|
gemcitabine • Hocena (antroquinonol)
3years
Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer (clinicaltrials.gov)
P1/2, N=52, Recruiting, Golden Biotechnology Corporation | Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2021 --> Jun 2022
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
CA 19-9 (Cancer antigen 19-9)
|
albumin-bound paclitaxel • Hocena (antroquinonol)
over3years
4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis. (PubMed, Int J Mol Sci)
In summary, our findings provide strong evidence regarding the therapeutic effect of 4-AAQB on KRAS-mutant CRC cells. Furthermore, 4-AAQB effectively inhibits Ras singling in CRC cells, through which KRAS-mutant CRC can be resensitized to cetuximab.
Journal
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12V • KRAS G12A • KRAS G12 • KRAS G13
|
Erbitux (cetuximab) • Hocena (antroquinonol)
over3years
4-Acetylantroquinonol B downregulates CDK2/CDK4 expression and DNA damage response signaling for triggers programmed cell death in triple negative breast cancer cells. (PubMed, Toxicol Appl Pharmacol)
The CDK2/4 expression level and DNA damage response (DDR) signaling are prominent in TNBC cell cycle regulation. We also evidenced the potential of a natural small compound, 4-AAQB, in therapy targeting the CDK2/4 and DDR in TNBC cells.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • CDK2 (Cyclin-dependent kinase 2)
|
HER-2 negative • CDK2 expression • CDK6 expression
|
Hocena (antroquinonol)
almost4years
The NF-[Formula: see text]B Signaling and Wnt/[Formula: see text]-catenin Signaling in MCF-7 Breast Cancer Cells in Response to Bioactive Components from Mushroom Antrodia Camphorata. (PubMed, Am J Chin Med)
The anti-inflammatory and antitumorigenic functions of Antroquinonol (AQ) and 4-Acetylantroquinonol B (4-AAQB) from AC were examined on breast cancer cell line MCF-7 with/without TNF-[Formula: see text] stimulation...The luciferase assay demonstrated that both components exhibited inhibitory effect on NF-[Formula: see text]B signaling and Wnt/[Formula: see text]-catenin signaling in the condition without TNF-[Formula: see text] stimulation. In conclusion, our results displayed an overall pattern that AQ and 4-AAQB possess potential anti-inflammatory and antitumorigenic functions in MCF-7 breast cancer cells and warranted further in vivo pre-clinical and clinical studies to explore their anticancer properties.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • IL6 (Interleukin 6) • IL10 (Interleukin 10) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • CCL2 (Chemokine (C-C motif) ligand 2)
|
IL6 elevation
|
Hocena (antroquinonol)
over5years
Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC (clinicaltrials.gov)
P2; N=31; Completed; Sponsor: Golden Biotechnology Corporation; Recruiting --> Completed; N=60 --> 31
Enrollment change • Trial completion • Clinical
|
ALB (Albumin)
|
Hocena (antroquinonol)